Author: Ravi Shankar

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron’s first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million

TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to provide additional supply of Inmazeb^® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for U.S. preparedness against Ebola disease. Inmazeb was the first Ebola treatment approved by the U.S. Food and Drug Administration (FDA), indicated specifically for infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to infected mothers, and has been administered to hundreds of patients since 2019. In a clinical trial, Inmazeb reduced mortality by approximately 55 percent compared to an active control treatment in patients with low viral load. This agreement continues a partnership that began with BARDA’s original procurement of the treatment in 2020.

Under the new agreement, Regeneron expects to deliver additional treatment doses of Inmazeb treatment to the U.S. government through 2031 and receive payment of approximately $270 million.

“Maintaining a ready supply of Inmazeb is exactly the kind of preparedness this country needs for the threats we can already see on the horizon,” said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron. “This extended agreement reflects the strength of our long-standing collaboration with BARDA and our shared commitment to ensuring that at-the-ready medicines are available whenever an Ebola outbreak occurs.”

Maftivimab Development Program

Separately, Regeneron’s investigational maftivimab monotherapy is being added to the PARTNERS trial to assess use as a potential treatment in the current Bundibugyo virus disease outbreak

Maftivimab has demonstrated positive in vitro and non-human primate activity against Bundibugyo; preprint data now available

Separate from the Inmazeb procurement agreement, Regeneron is evaluating maftivimab, the most potent virus-neutralizing component of Inmazeb, as a potential treatment for Ebola disease caused by Bundibugyo virus, the orthoebolavirus driving the current outbreak in the Democratic Republic of the Congo (DRC) and for which there are no currently approved treatment options. Maftivimab has demonstrated strong efficacy against Bundibugyo virus in in vitro and non-human primate (NHP) studies, supporting its continued development as a monotherapy or combination treatment candidate. These data are now available in preprint on BioRxiv.org and pending peer review publication.

“Inmazeb was created by Regeneron scientists in record time using our proprietary VelociSuite^® rapid-response technologies,” said George D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer of Regeneron. “We are now advancing maftivimab, which has already demonstrated positive results in non-human primates infected with Bundibugyo, so that we can bring another potential Ebola treatment forward as quickly as possible to help in the current outbreak. Regeneron’s continued supply of Inmazeb to the U.S. government, our advancement of maftivimab and our partnerships to support frontline response capacity reflect the Company’s long-term commitment to infectious diseases preparedness, from the laboratory to the communities most affected by outbreaks.”

Based on in vitro and NHP efficacy studies, maftivimab is being added to the PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) clinical trial, which is evaluating potential treatments for Bundibugyo virus disease. PARTNERS is delivered through a global partnership of Ministries of Health, researchers, healthcare workers and international research and non-governmental organizations. The trial has been designed and is coordinated internationally by the Pandemic Sciences Institute, University of Oxford, and is being led nationally in the DRC by the Institut National de Recherche Biomédicale (INRB), supported by the Institute of Tropical Medicine (ITM), Antwerp. The trial is sponsored by the World Health Organization (WHO) and is made possible with the support of Africa CDC.

Regeneron also continues to support Afya Foundation’s emergency response efforts aimed at safeguarding frontline healthcare workers and strengthening healthcare system resilience during the current outbreak.

About Inmazeb
Inmazeb is approved by the U.S. FDA for the treatment of infection caused by Orthoebolavirus zairense (formerly known as Zaire ebolavirus) in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. Inmazeb was created using Regeneron’s
VelocImmune^® platform and associated VelociSuite^® technologies. The treatment consists of three monoclonal antibodies that help neutralize the Ebola virus by blocking its ability to invade a patient’s cells and/or enlisting other immune cells to target infected cells and remove them from the body.

The safety and efficacy of Inmazeb was established through the 681-patient PALM Trial, which was independently conducted by the WHO, the U.S. National Institutes of Health and the INRB during the 2018 DRC outbreak of Ebola virus. In 2019, as reported in the New England Journal of Medicine, the PALM Trial was stopped early following a pre-specified interim analysis that showed the superiority of Inmazeb in preventing death versus two other investigational treatments.

Inmazeb was approved by the FDA in 2020, and in 2022, WHO published its first guidelines for Ebola virus therapeutics, which strongly recommends the use of Inmazeb for treatment of Ebola virus infection and calls on the global community to engage all possible mechanisms to improve access to life-saving Ebola disease medicines. In November 2023, Inmazeb became the first and only Ebola disease treatment to be prequalified by the WHO, certifying that the medicine meets WHO’s standards for quality, safety and efficacy and is considered “essential.”

Since 2018, Inmazeb has been offered by Regeneron at no cost under a compassionate use protocol to infected persons in countries experiencing an Ebola virus disease outbreak caused by Orthoebolavirus zairense, including the DRC and Guinea. In September 2025, the company committed to donate up to 500 doses of Inmazeb to the WHO for exclusive use by governments of low- and lower-middle income countries that are most at-risk for Ebola disease outbreaks.¹ In addition, Regeneron has worked with governments in higher- and middle-income countries to establish Inmazeb stockpiles.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract numbers HHSO100201700016C and HHSO100201500013C. The contract and federal funding are not an endorsement of the product or company.

IMPORTANT SAFETY INFORMATION AND INDICATION WARNINGS AND PRECAUTIONS FOR INMAZEB

Hypersensitivity Reactions Including Infusion-Associated Events: Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with INMAZEB. These may include acute, life-threatening reactions during and after the infusion. Monitor all patients for signs and symptoms including, but not limited to, hypotension, chills and elevation of fever, during and following INMAZEB infusion. In the case of severe or life-threatening hypersensitivity reactions, discontinue the administration of INMAZEB immediately and administer appropriate emergency care.

Infusion could not be completed in 1% of subjects who received INMAZEB due to infusion-associated adverse events. The rate of infusion of INMAZEB may be slowed or interrupted if the patient develops any signs of infusion-associated events or other adverse events.

ADVERSE REACTIONS: The most common adverse events reported in at least 20% of subjects who received INMAZEB were pyrexia (or elevation in fever), chills, tachycardia, tachypnea and vomiting. The evaluation of adverse events in subjects who received INMAZEB may have been confounded by the signs and symptoms of the underlying Orthoebolavirus zairense infection.

DRUG INTERACTIONS: INMAZEB may reduce the efficacy of live vaccine, therefore, avoid the concurrent administration of a live vaccine during treatment with INMAZEB. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. The efficacy of INMAZEB among subjects who reported receipt of a recombinant live vaccine prior to their enrollment in the PALM clinical trial was similar to subjects who did not receive a vaccine.

INDICATION
INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection.

Limitations of Use: The efficacy of INMAZEB has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera. Orthoebolavirus zairense can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Orthoebolavirus zairense strains when deciding to use INMAZEB.

Please see accompanying full Prescribing Information for Inmazeb.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Inmazeb^® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of infection caused by Orthoebolavirus zairense (also known as Ebola virus) as well as maftivimab as a potential treatment for Bundibugyo ebolavirus; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products (including Inmazeb) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as maftivimab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates (such as maftivimab) and new indications for Regeneron’s Products; whether and the extent to which Regeneron will be able to deliver the additional treatment doses of Inmazeb set forth in its agreement with the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services (collectively, the “U.S. Government”) discussed in this press release (the “Supply Agreement”), the amount of payments (if any) Regeneron may receive pursuant to the Supply Agreement, and whether the Supply Agreement is terminated by the U.S. Government or otherwise prior to completion; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates (such as maftivimab); the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA^® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025, and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Media Contact for Regeneron
Alexandra.bowie@regeneron.com

Investor Contact for Regeneron
Vesna.tosic@regeneron.com

_________________
¹ As defined by the World Bank based on gross national income per capita.

ROUYN-NORANDA, Quebec, Oct. 26, 2026 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Company”) is pleased to provide an update on its mining and gold milling operations for the month of September. This latest update demonstrates accelerating progress across all production indicators compared to the results presented in the previous report.

Operating Highlights:

• Feed Volume: A total of 7,253 tonnes of ore was crushed, and 6,739 tonnes were milled during the period.
• Average Grade: The overall average mill feed grade reached 3.42 g/t gold.
• Gold Production: The mill generated 740 oz of gold, supported by a strong recovery rate of 94.1%.
• Metal Pours: A total of 545 oz of gold was officially poured during the month of September.
• In-Circuit Inventory: At the end of the period, 741 oz of gold remained in the mill circuit (work-in-progress inventory), representing significant latent value for upcoming pours.

Detailed Feed Sources:

The Company optimized its mill feed by blending higher-grade ore from underground workings with surface stockpiles:

1. Underground Production: 5,582 tonnes extracted directly from the underground deposit, averaging 3.62 g/t gold.
2. Low-Grade Stockpile: 1,157 tonnes sourced from the historical low-grade stockpile, successfully reclaimed and converted into mill feed at an average of 2.41 g/t gold.

The comparative table below highlights the operational performance growth between August and September:

Operational Indicator	August		September		Net Progress
Milled Tonnes	6,209 tonnes		6,739 tonnes		+ 530 tonnes (+ 8.5%)
Grade	1.94 g/t Au		3.42 g/t Au		+ 1.48 g/t Au (+ 76.3%)
Recovery Rate	88.9%		94.1%		+ 5.2%
Gold Production	344 oz		740 oz		+ 396 oz (+ 115.1%)

With the month of October well underway, the Company is also proud to announce its progress across various development faces:

Sector	Progress	Planned Production Period
295-DAC5	512 m / 790 m	Mining underway; completion expected in February 2027 for the West 1 ore zone.
235-Zone 20	524.9 m / 516 m (Completed)	September – January 2027
235-Zone 3	266.9 m / 405 m	Upcoming (post-development)
355-Zone 3N	Development started +13.9 m, ore drift completed	Upcoming
235-Zone 4_5	Ore drift completed. Haulage drifts (south side) completed. Sub-level #1 started + 48.85 m of development.	Multi-year

Pascal Hamelin, President and Chief Executive Officer of Abcourt, stated: “September’s results show solid progress in our operations and confirm that our mill is gaining efficiency. Doubling our gold production in a single month, while achieving a 94.1% recovery rate, is a testament to the quality of our operational planning and the constant efforts of our teams on the ground. Optimizing our mill feed by blending higher-grade underground ore with reclaimed surface stockpiles is clearly paying off and validates our gradual growth model. Furthermore, with a second mill crew currently in training this week, we will be able to process more ore starting in November.”

Qualified Person: Pascal Hamelin, P. Eng., President and Chief Executive Officer of the Company, has reviewed and approved the technical information contained in this press release. Mr. Hamelin is a Qualified Person as defined by National Instrument 43-101.

About Abcourt Mines Inc.

Abcourt Mines Inc. is a Canadian gold development company with strategic properties located in northwestern Quebec, Canada. Abcourt owns the Sleeping Giant mine and mill and the Flordin property where it concentrates its activities.

For further information on Abcourt Mines Inc., please visit our website www.abcourt.ca and the documents filed under our profile on the SEDAR+ website www.sedarplus.ca.

Pascal Hamelin	Dany Cenac Robert
President and Chief Executive Officer	VP Communication and Corporate Development
T: (819) 768-2857	T: (514) 722-2276, ext. 456
Email: phamelin@abcourt.com	Email: ir@abcourt.com

FORWARD-LOOKING STATEMENTS

Certain information contained in this press release may constitute “forward-looking information” within the meaning of Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “aims”, “expects”, “projects”, “intends”, “anticipates”, “estimates”, “could”, “should”, “likely”, or variations of such words and phrases or statements specifying that certain acts, events or results “could”, “should” occur, “will occur” or “will be achieved” or other similar expressions. Forward-looking statements are based on Abcourt’s estimates and are subject to known and unknown risks, uncertainties and other factors that could cause actual results, level of activity, performance or achievements of Abcourt to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Forward-looking statements are subject to business and economic factors and uncertainties, as well as other factors that could cause actual results to differ materially from those forward-looking statements, including relevant assumptions and risk factors set forth in Abcourt’s public documents, available on SEDAR+ at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Although Abcourt believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements. Unless required by applicable securities laws, Abcourt disclaims any intention or obligation to update or revise any of these forward-looking statements or information, whether in light of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026.

In connection with the earnings release, Syndax’s management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 2, 2026.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax3Q26
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-3q26.open-exchange.net/

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

WARSAW, Ind., Oct. 26, 2026 (GLOBE NEWSWIRE) — Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported record third quarter net income of $28.9 million for the three months ended September 30, 2026, which represents an increase of $2.5 million, or 9%, compared to net income of $26.4 million for the three months ended September 30, 2025. Diluted earnings per share of $1.14 for the third quarter of 2026 also represents a record for third quarter performance and increased $0.11, or 11%, compared to $1.03 for the third quarter of 2025. On a linked quarter basis, net income increased $417,000 from $28.4 million. Diluted earnings per share increased $0.01 from $1.13 on a linked quarter basis.

The company further reported record performance year-to-date with net income of $83.8 million for the nine months ended September 30, 2026, versus $73.5 million for the corresponding period of 2025, an increase of $10.3 million, or 14%. Diluted earnings per share increased $0.46, or 16%, to $3.31 for the nine months ended September 30, 2026, versus $2.85 for the corresponding period of 2025.

Total revenue was $73.0 million for the third quarter of 2026 representing an increase of $4.0 million, or 6%, as compared to $69.0 million for the third quarter of 2025. On a linked quarter basis, total revenue increased by $2.1 million, or 3%, from $70.9 million in the second quarter of 2026. Total revenue increased by $14.4 million, or 7%, to $213.6 million for nine months ended September 30, 2026, as compared to $199.2 million for the corresponding period of 2025.

“Strong loan growth and healthy net interest margin expansion were reflected in the quality of our earnings performance in the quarter,” commented David M. Findlay, Chairman and CEO. “Clearly, the resulting record net income reflects the efforts of the entire Lake City Bank team as we continue to grow our market share in every market we serve.”

Quarterly Financial Performance

Third Quarter 2026 versus Third Quarter 2025 highlights:

• Loans increased by $431.4 million, or 8%, from $5.25 billion to $5.68 billion
• Average loans increased by $381.9 million, or 7%, to $5.59 billion
• Net interest income improved by $4.6 million, or 8%, from $56.1 million to $60.7 million
• Net interest margin improved 8 basis points to 3.58% from 3.50%
• Total revenue grew by 6% from $69.0 million to $73.0 million
• Core deposits expanded by $204.3 million, or 3%, to $6.05 billion
• Return on average equity improved to 14.88%, compared to 14.60%
• Average equity improved by $51.7 million, or 7%, from $717.4 million to $769.1 million
• Return on average assets improved to 1.59%, compared to 1.53%
• Nonperforming loans to total loans improved to 0.32%, from 0.36%
• Diluted weighted average common shares outstanding declined by 583,478, or 2%, as a result of the company’s ongoing share repurchase plan

Third Quarter 2026 versus Second Quarter 2026 highlights:

• Net interest margin improved 9 basis points to 3.58% from 3.49%
• Loans grew by $100.4 million, or 2%, from $5.58 billion to $5.68 billion
• Net interest income increased $2.4 million, or 4%, from $58.3 million to $60.7 million
• Average loans increased by $56.4 million, or 1%, to $5.59 billion
• Core deposits expanded by $22.5 million, or less than 1%, to $6.05 billion
• Total revenue grew by 3% from $70.9 million to $73.0 million
• Nonperforming loans declined by $2.0 million, or 10%, from $20 million to $18 million

Net Interest Margin

Net interest margin was 3.58% for the third quarter of 2026, representing an 8 basis point increase from 3.50% for the third quarter of 2025. Net interest margin was favorably impacted by a reduction in deposit pricing that outpaced the decline in earning asset yields. The company’s funding costs fell by 24 basis points from 2.37% for the third quarter of 2025 to 2.13% for the third quarter of 2026. Offsetting the decrease in funding costs was a decrease to earning asset yields of 16 basis points from 5.87% for the third quarter of 2025 to 5.71% for the third quarter of 2026.

Net interest margin increased 9 basis points to 3.58% for the third quarter of 2026, as compared to 3.49% for the linked second quarter of 2026. Average earning asset yields increased by 6 basis points from 5.65% to 5.71% on a linked quarter basis and interest expense as a percentage of average earning assets decreased 3 basis points from 2.16% to 2.13%. The second quarter cost of funds were elevated by inflows of seasonal public funds deposits into higher priced deposit products.

Net interest income was $60.7 million for the third quarter of 2026, representing an increase of $4.6 million, or 8%, as compared to $56.1 million for the third quarter of 2025. On a linked quarter basis, net interest income increased by $2.4 million, or 4%, from $58.3 million. Net interest income increased by $12.0 million, or 7%, from $163.8 million for the nine months ended September 30, 2025, to $175.8 million for the nine months ended September 30, 2026.

“We’re particularly proud of the net interest margin expansion on a year-over-year basis as well as on a quarter-linked basis. This significant improvement reflects the positive impact of healthy loan growth combined with deposit pricing strategies to positively impact our net interest margin,” stated Lisa M. O’Neill, Executive Vice President and Chief Financial Officer.

Capital Strength

The company’s total capital as a percentage of risk-weighted assets was 15.56% at September 30, 2026, compared to 16.21% at September 30, 2025, and 15.61% at June 30, 2026. These capital levels significantly exceeded the 10.00% regulatory threshold required to be characterized as “well capitalized” and reflect the company’s robust capital base.

The company’s tangible common equity to tangible assets ratio, which is a non-GAAP financial measure, was 10.11% at September 30, 2026, compared to 10.79% at September 30, 2025, and 10.63% at June 30, 2026. The decline in the tangible common equity to tangible assets ratio was primarily driven by an increase in unrealized losses from available-for-sale investment securities, resulting from the rapid 85 basis point rise in the 10-year Treasury yield during the third quarter. As a result, unrealized losses on available-for-sale investment securities increased to $213.9 million at September 30, 2026, up from $159.9 million at September 30, 2025, and $140.9 million at June 30, 2026. Excluding the impact of accumulated other comprehensive income (loss) on tangible common equity and tangible assets, the company’s ratio of adjusted tangible common equity to adjusted tangible assets, a non-GAAP financial measure, was 12.32% at September 30, 2026, compared to 12.57% at September 30, 2025, and 12.14% at June 30, 2026.

The company continued to repurchase shares during the third quarter, with 41,550 shares of its common stock repurchased at a weighted average price per share of $58.45 with an aggregate purchase price of $2.4 million. The current program authorizes the company to repurchase up to $60.0 million in aggregate purchase price of the company’s common stock through April 30, 2027, or 8.2% of current equity. The company has repurchased a total of 787,166 shares under the current program from April 1, 2025 through September 30, 2026 at an aggregate purchase price of $45.4 million and weighted average purchase price per share of $57.62, with remaining authorization of $14.6 million at quarter end.

As announced on October 13, 2026, the board of directors approved a cash dividend for the third quarter of $0.52 per share, payable on November 5, 2026, to shareholders of record as of October 25, 2026. The third quarter dividend per share represents a 4% increase from the $0.50 dividend per share paid for the third quarter of 2025. The dividend payout ratio improved to 47.1% for the nine months ended September 30, 2026 compared to 52.6% for the similar period in 2025.

Kristin L. Pruitt, President, noted, “We are pleased to continue to opportunistically leverage our share repurchase program to demonstrate our confidence in the quality of our performance and the long-term strength of our model, as well as our earnings potential. Our capital position remains robust, enabling us to grow the balance sheet while also returning excess capital to shareholders through a meaningful dividend as well as the common share repurchases.” 

Loan Portfolio

Average total loans of $5.59 billion in the third quarter of 2026 increased $381.9 million, or 7%, from $5.21 billion for the third quarter of 2025, and increased $56.4 million, or 1%, from $5.53 billion for the second quarter of 2026.

Total loans, net of deferred loan fees, increased by $431.4 million, or 8%, from $5.25 billion as of September 30, 2025, to $5.68 billion as of September 30, 2026. The growth in loans was driven by increases across all primary commercial and consumer segments of the portfolio, with increases to the commercial and industrial loans of $187.4 million, or 12%, commercial real estate and multi-family residential loans of $117.6 million, or 4%, consumer 1-4 family mortgage loans of $83.2 million, or 16%, other commercial loans of $28.8 million, or 31%, agri-business and agricultural loans of $8.2 million, or 2%, and other consumer loans of $6.7 million, or 6%.

On a linked quarter basis, total loans increased by $100.4 million, or 2%, from $5.58 billion at June 30, 2026. The linked quarter increase was driven by growth in both the commercial and consumer segments of the portfolio, with increases to the commercial and industrial loan portfolio of $61.1 million, or 4%, consumer 1-4 family mortgage loans of $18.0 million, or 3%, commercial real estate and multi-family residential loans of $12.2 million, or less than 1%, and agri-business and agricultural loans of $8.8 million, or 3%.

Commercial loan originations for the third quarter were approximately $525.0 million and were offset by approximately $443.0 million in loan pay downs. Commercial and industrial line of credit usage was 42% as of September 30, 2026, compared to 40% at September 30, 2025, and 43% at June 30, 2026. Total commercial and industrial lines of credit availability grew by $104.0 million, or 5%, as compared to the prior year, and line usage increased by $88.0 million, or 10%, over that period. On a linked quarter basis, total commercial and industrial lines of credit availability declined by $2.0 million, and line usage declined by $16.0 million, or 2%.

“The strength of loan growth during 2026 has been highlighted by double digit growth in commercial and industrial loans. This encouraging trend is further supported by commercial loan originations outpacing loan paydowns for the fourth quarter in a row,” stated Findlay. “We continue to make progress on our organic loan growth plans with high single digit loan growth on a year-over-year and quarter-linked bases. We are optimistic that our continued emphasis on client prospecting and joint calling is beginning to yield positive results. We continue to add to our commercial and retail lending teams throughout the Lake City Bank footprint.”

Diversified Deposit Base

The bank’s diversified deposit base has grown on a year-over-year basis and core deposits, which exclude brokered deposits, represented 96% of total deposits at September 30, 2026.

(in thousands)	September 30, 2026							June 30, 2026							September 30, 2025
Retail	$	1,817,961			28.9	%		$	1,769,029			28.0	%		$	1,724,983			28.6	%
Commercial		2,210,358			35.1				2,113,784			33.4				2,288,701			38.0
Public funds		2,024,628			32.2				2,147,600			33.9				1,834,987			30.5
Core deposits		6,052,947			96.2				6,030,413			95.3				5,848,671			97.1
Brokered deposits		241,849			3.8				299,155			4.7				175,647			2.9
Total	$	6,294,796			100.0	%		$	6,329,568			100.0	%		$	6,024,318			100.0	%

Total deposits increased $270.5 million, or 4%, from $6.02 billion as of September 30, 2025, to $6.29 billion as of September 30, 2026. The increase in total deposits was driven by an increase in core deposits, which increased by $204.3 million, or 3%. Public funds deposits grew annually by $189.6 million, or 10%, to $2.02 billion and retail deposits expanded by $93.0 million, or 5%, to $1.82 billion. Conversely, commercial deposits contracted by $78.3 million, or 3%, to $2.21 billion. Brokered deposits increased by $66.2 million, or 38%, but remain at a low level, representing 4% of total deposits at September 30, 2026.

On a linked quarter basis, total deposits decreased $34.8 million, or 1%, from $6.33 billion at June 30, 2026, to $6.29 billion at September 30, 2026. Core deposits increased by $22.5 million, or less than 1%, while brokered deposits decreased by $57.3 million, or 19%. The linked quarter growth in core deposits was driven by an increase in commercial deposits of $96.6 million, or 5%, and an increase in retail deposits of $48.9 million, or 3%. This growth was offset by a seasonal reduction in public funds of $123.0 million, or 6%.

Average total deposits were $6.34 billion for the third quarter of 2026, an increase of $308.5 million, or 5%, from $6.03 billion for the third quarter of 2025. Average interest-bearing deposits drove the increase in average total deposits and increased by $259.3 million, or 5%. Contributing to the overall growth of interest-bearing deposits was an increase in total average time deposits of $174.4 million, or 23%, and an increase in average interest-bearing checking accounts of $88.6 million, or 2%. Additionally, average noninterest-bearing demand deposits increased by $49.3 million, or 4%, to $1.29 billion.

On a linked quarter basis, average total deposits increased by $25.4 million, or less than 1%, from $6.31 billion for the second quarter of 2026 to $6.34 billion for the third quarter of 2026. Driving the increase was an increase in noninterest bearing demand deposits of $65.9 million, or 5%, and an increase in average time deposits of $13.3 million, or 1%. Offsetting these increases were reductions in interest bearing checking accounts, which declined by $47.1 million, or 1%, and average savings accounts, which declined by $6.7 million, or 2%.

Checking account growth as of September 30, 2026, compared to September 30, 2025, includes growth of $261.3 million, or 15%, in aggregate public fund checking account balances and growth of $43.5 million, or 5%, in aggregate retail checking account balances. Offsetting these increases was a decline of $128.2 million, or 6%, in aggregate commercial checking account balances. The number of accounts expanded for all three segments, with growth of 2% for commercial accounts, 1% for public funds accounts and 1% for retail accounts.

“Core deposits remain stable at 96% of total deposits,” added O’Neill. “During the quarter we deployed deposit growth strategies in Indianapolis that yielded $106.1 million in deposits, of which $83.2 million was new money to Lake City Bank. This strategy contributed to the quarter linked growth in commercial and retail deposits and provides our revenue producing teams with new opportunities to continue to grow deposit and loan relationships.”

Asset Quality

The company recorded a provision for credit losses of $1.2 million in the third quarter of 2026, compared to $2.0 million in the third quarter of 2025 and $1.7 million for the linked second quarter of 2026.

The allowance for credit loss reserve to total loans was 1.21% at September 30, 2026, down from 1.30% at September 30, 2025, and 1.27% at June 30, 2026. The company recorded net charge offs of $3.0 million in the third quarter of 2026, compared to net charge offs of $384,000 in the third quarter of 2025 and $24,000 during the linked second quarter of 2026. Net charge offs during the third quarter of 2026 were driven by a partial charge off of $2.8 million to address a shortfall in collateral related to the ongoing workout of a nonperforming commercial credit, which was fully reserved for in prior quarters. Annualized net charge offs to average loans were 0.21% for the third quarter of 2026, compared to 0.03% for the third quarter of 2025 and 0.00% for the linked second quarter of 2026.

Nonperforming assets decreased by $1.1 million, or 6%, to $18.0 million as of September 30, 2026, versus $19.1 million as of September 30, 2025. On a linked quarter basis, nonperforming assets decreased by $2.0 million, or 10%, primarily driven by the aforementioned $2.8 million partial charge off. The ratio of nonperforming assets to total assets at September 30, 2026, decreased to 0.25%, down from 0.28% at September 30, 2025 and June 30, 2026.

Total individually analyzed and watch list loans increased by $44.7 million, or 28%, to $202.0 million as of September 30, 2026, versus $157.2 million as of September 30, 2025. On a linked quarter basis, total individually analyzed and watch list loans increased by $4.0 million, or 2%, from $198.0 million at June 30, 2026. The increase in individually analyzed and watch list loans during the linked quarter was driven primarily by credit downgrades to the watch list of approximately $15.6 million and offset by payoffs and upgrades of approximately $9.4 million and the $2.8 million partial charge off. Watch list loans as a percentage of total loans were 3.56% at September 30, 2026, a 56 basis point increase compared to 3.00% at September 30, 2025, and a 1 basis point increase from 3.55% at June 30, 2026.

Findlay stated, “The Indiana economy is resilient, diverse and expanding. Our borrowers continue to navigate through the challenges created by rising oil prices and tariff policy uncertainty. We are pleased that our asset quality trends continue to be stable with historically-low troubled loan totals, and we remain optimistic about the manufacturing outlook in our state.”

Investment Portfolio Overview

Total investment securities were $1.09 billion at September 30, 2026, reflecting a decrease of $74.3 million, or 6%, as compared to $1.16 billion at September 30, 2025. Investment securities represented 15% of total assets as of September 30, 2026, down from 17% at September 30, 2025 and 16% at June 30, 2026. The company anticipates receiving principal and interest cash flows of approximately $24.1 million during the remainder of 2026 from the investment securities portfolio and plans to use that liquidity to fund loan growth as well as reinvestments to the investment securities portfolio. Tax equivalent adjusted effective duration for the investment portfolio contracted to 5.6 years at September 30, 2026, compared to 5.8 years at September 30, 2025, and 5.8 years at June 30, 2026.

Noninterest Income

The company’s noninterest income decreased $680,000, or 5%, to $12.3 million for the third quarter of 2026, compared to $13.0 million for the third quarter of 2025. Wealth advisory fees increased $298,000, or 10%, driven by continued growth in customers and assets under management. Mortgage banking income increased $94,000 from increased pipeline volume. Service charges on deposit accounts increased by $84,000, or 3%. Equity market declines negatively impacted the performance of the bank’s variable owned life insurance policies, which declined by $476,000 during the third quarter of 2026 as compared to the prior quarter. Loan and service fees decreased $384,000, or 11%, from reduced commercial loan fees. Other income decreased by $320,000, or 43%, from a reduction in limited partnership investment income.

Noninterest income for the third quarter of 2026 decreased by $298,000, or 2%, on a linked quarter basis from $12.6 million during the second quarter of 2026. Increases to fee-based revenue streams benefitted noninterest income, including wealth advisory fees, which increased $136,000, or 5%, service charges on deposit accounts, which increased $127,000, or 4%, merchant and interchange fee income, which increased $40,000, or 5%, and investment brokerage fees, which increased $24,000, or 5%. Offsetting these positive contributions to noninterest income were decreases to bank owned life insurance income of $464,000, or 29%, other income of $96,000, or 18%, and mortgage banking income of $40,000, or 31%. The decrease in bank owned life insurance income was driven by variable bank owned life insurance market performance. Reduced limited partnership income primarily drove the decrease in other income, and reduced pipeline volume contributed to the decrease in mortgage banking income.

Noninterest income increased by $2.4 million, or 7%, to $37.8 million for the nine months ended September 30, 2026, compared to $35.4 million for the prior year period. Increases in fee-based revenue streams contributed to the increase to noninterest income, with wealth advisory fees improving by $844,000, or 10%, and service charges on deposit accounts improving by $235,000, or 3%. Conversely, merchant and interchange fee income declined $79,000, or 3%. Bank owned life insurance income improved by $817,000, or 28%, from improved market performance from variable bank owned life insurance policies and incremental income from general account policies purchased in 2025. Interest rate swap fee income improved by $681,000 and mortgage banking income improved $230,000, or 343%, from increased volume.

“Our fee-based generating lines of business are contributing to revenue growth with high single digit year-over-year growth in noninterest income,” added Findlay. “We are seeing our investments in these business lines positively impact revenue outcomes. In particular, our Wealth Advisory fees grew by 10% on a year-to-date basis compared to the same period in 2025.”

Noninterest Expense

Noninterest expense increased $1.2 million, or 3%, to $36.1 million for the third quarter of 2026, compared to $35.0 million during the third quarter of 2025. Salaries and employee benefits expense increased by $368,000, or 2%, primarily as a result of increased salaries and wages and benefits expense, and was offset by reduced performance-based incentive compensation accruals. Full-time equivalent staff increased by 31 persons at September 30, 2026 compared to the same period in the prior year, or 5%. The growth in staff reflects the organic growth plans with an increase of 18 revenue generating personnel and 13 support staff over the past year. Professional fees increased $397,000, or 23%, from increased technology implementation fees and other professional expenses. Net occupancy expense increased $276,000, or 15%, from the company’s continued expansion and reinvestment into its physical branch and operational infrastructure, including the Innovation and Technology Center at the company’s downtown Warsaw campus. Data processing fees and supplies increased $234,000, or 6%, from continued investment in customer-facing and operational technology solutions, including artificial intelligence capabilities. Offsetting these increases was a decrease in other expense of $175,000, or 6%. The reduction in other expense was driven by reduced office supplies and telecommunications expenses.

On a linked quarter basis, noninterest expense increased by $1.7 million, or 5%, from $34.5 million during the second quarter of 2026. Other expense increased $436,000, or 19%, primarily from semi-annual board of directors share grants that occurred in the third quarter. Corporate and business development expense increased by $388,000, or 31%, from increased advertising, client entertainment and business development expenses. Professional fees increased $338,000, or 19%, from increased technology implementation fees and other professional fees. Salaries and employee benefits expense increased $288,000, or 1%, primarily from increased health insurance expense. Net occupancy expense increased by $186,000, or 9%. 

Noninterest expense increased by $7.6 million, or 8%, for the nine months ended September 30, 2026, to $105.7 million compared to $98.2 million for the comparable period of 2025. Salaries and employee benefits expense increased $6.2 million, or 11%, primarily due to increased salaries and wages of $2.9 million, performance-based incentive compensation accruals of $1.6 million, health insurance expense of $1.3 million, and variable deferred compensation expense of $370,000. Net occupancy expense increased $620,000, or 11%, from investing in our retail branch and operational infrastructure. Data processing fees and supplies expense increased $450,000, or 4%, from continued investment in customer-facing and operational technology solutions. Corporate and business development expense increased $236,000, or 6%, from increased advertising and corporate development expenses. FDIC insurance and other regulatory fees increased $147,000, or 6%, from increased FDIC insurance premium accruals due to balance sheet growth.

The company’s efficiency ratio was 49.5% for the third quarter of 2026, compared to 50.7% for the third quarter of 2025 and 48.6% for the linked second quarter of 2026. The company’s efficiency ratio was 49.5% for the nine months ended September 30, 2026, compared to 49.3% for the comparable period in 2025.

“During 2026, we have made significant investments in people, brick and mortar and technology,” Findlay stated. “Our staffing focus has been on the addition of revenue producing team members, primarily in commercial banking.  In addition, we continue to invest in our footprint expansion in all Lake City Bank markets. We currently have three branches under development in the Indianapolis and Fort Wayne markets, and we opened the company’s Innovation and Technology Center in our Warsaw headquarters. Innovation that focuses on artificial intelligence capabilities is also a priority as we prepare for the rollout of our innovative, new customer relationship management program that will enhance relationship development and expansion, client communication, and allow for future revenue growth.”

Information regarding Lakeland Financial Corporation may be accessed on the home page of its subsidiary, Lake City Bank, at lakecitybank.com. The company’s common stock is traded on the Nasdaq Global Select Market under “LKFN.” Lake City Bank, a $7.2 billion bank headquartered in Warsaw, Indiana, was founded in 1872 and serves Central and Northern Indiana communities with 55 branch offices and a robust digital banking platform. Lake City Bank’s community banking model prioritizes building in-market long-term customer relationships while delivering technology-forward solutions for retail and commercial clients.

This document contains, and future oral and written statements of the company and its management may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations, plans, objectives, performance and business of the company. Forward-looking statements, which may be based upon beliefs, expectations and assumptions of the company’s management and on information currently available to management, are generally identifiable by the use of words such as “believe,” “expect,” “anticipate,” “continue,” “plan,” “intend,” “estimate,” “may,” “will,” “would,” “could,” “should” or other similar expressions. The company’s ability to predict results or the actual effect of the company’s operating environment or its plans or strategies is inherently uncertain and, accordingly, the reader is cautioned not to place undue reliance on any forward-looking statements made by the company. Additionally, all statements in this document, including forward-looking statements, speak only as of the date they are made, and the company undertakes no obligation to update any statement in light of new information or future events. Numerous factors could cause the company’s actual results to differ from those reflected in forward-looking statements, including the effects of economic, business and market conditions and changes, particularly in our Indiana market area, including prevailing interest rates and the rate of inflation; governmental trade, monetary and fiscal policies; including any effects resulting from international government conflicts; the risks of changes in interest rates on the levels, composition and costs of deposits, loan demand and the values and liquidity of loan collateral, securities and other interest sensitive assets and liabilities; changes in borrowers’ credit risks and payment behaviors; and developments in technology, as well as those identified in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are incorporated herein by reference.

LAKELAND FINANCIAL CORPORATION THIRD QUARTER 2026 FINANCIAL HIGHLIGHTS
	Three Months Ended												Nine Months Ended
(unaudited – dollars in thousands, except per share data)	September 30,				June 30,				September 30,				September 30,				September 30,
END OF PERIOD BALANCES	2026				2026				2025				2026				2025
Assets	$	7,207,927			$	7,242,959			$	6,895,028			$	7,207,927			$	6,895,028
Investments		1,090,447				1,169,188				1,164,737				1,090,447				1,164,737
Loans		5,680,004				5,579,625				5,248,619				5,680,004				5,248,619
Allowance for Credit Losses		68,830				70,598				68,168				68,830				68,168
Deposits		6,294,796				6,329,568				6,024,318				6,294,796				6,024,318
Brokered Deposits		241,849				299,155				175,647				241,849				175,647
Core Deposits (1)		6,052,947				6,030,413				5,848,671				6,052,947				5,848,671
Total Equity		732,094				773,374				747,503				732,094				747,503
Goodwill Net of Deferred Tax Assets		3,803				3,803				3,803				3,803				3,803
Tangible Common Equity (2)		728,291				769,571				743,700				728,291				743,700
Adjusted Tangible Common Equity (2)		909,564				893,530				883,865				909,564				883,865
AVERAGE BALANCES
Total Assets	$	7,196,421			$	7,190,663			$	6,850,671			$	7,156,850			$	6,839,762
Earning Assets		6,837,770				6,832,702				6,492,640				6,800,353				6,498,243
Investments		1,151,647				1,161,807				1,127,094				1,167,769				1,129,664
Loans		5,587,744				5,531,344				5,205,833				5,520,526				5,207,205
Total Deposits		6,338,090				6,312,674				6,029,557				6,236,470				6,000,829
Interest Bearing Deposits		5,044,449				5,084,953				4,785,176				4,984,286				4,751,953
Interest Bearing Liabilities		5,062,655				5,133,439				4,818,115				5,067,118				4,807,547
Total Equity		769,133				760,533				717,428				767,524				703,564
INCOME STATEMENT DATA
Net Interest Income	$	60,721			$	58,301			$	56,073			$	175,795			$	163,824
Net Interest Income-Fully Tax Equivalent		61,836				59,404				57,180				179,118				167,150
Provision for Credit Losses		1,200				1,708				2,000				4,908				11,800
Noninterest Income		12,274				12,572				12,954				37,779				35,368
Noninterest Expense		36,121				34,457				34,965				105,729				98,160
Net Income		28,857				28,440				26,404				83,775				73,455
Pretax Pre-Provision Earnings (2)		36,874				36,416				34,062				107,845				101,032
PER SHARE DATA
Basic Net Income Per Common Share	$	1.15			$	1.14			$	1.03			$	3.33			$	2.86
Diluted Net Income Per Common Share		1.14				1.13				1.03				3.31				2.85
Cash Dividends Declared Per Common Share		0.52				0.52				0.50				1.56				1.50
Dividend Payout		45.61	%			46.02	%			48.54	%			47.13	%			52.63	%
Book Value Per Common Share (equity per share issued)	$	29.29			$	30.90			$	29.08			$	29.29			$	29.08
Tangible Book Value Per Common Share (2)		29.14				30.75				28.93				29.14				28.93
Market Value – High	$	64.55			$	63.03			$	69.40			$	64.55			$	71.77
Market Value – Low		57.40				56.56				59.08				54.36				50.00
Basic Weighted Average Common Shares Outstanding		25,027,394				25,058,539				25,703,699				25,142,662				25,708,543
	Three Months Ended												Nine Months Ended
(unaudited – dollars in thousands, except per share data)	September 30,				June 30,				September 30,				September 30,				September 30,
PER SHARE DATA (continued)	2026				2026				2025				2026				2025
Diluted Weighted Average Common Shares Outstanding		25,237,882				25,231,590				25,821,360				25,320,493				25,804,322
KEY RATIOS
Return on Average Assets		1.59	%			1.59	%			1.53	%			1.57	%			1.44	%
Return on Average Total Equity		14.88				15.00				14.60				14.59				13.96
Average Equity to Average Assets		10.69				10.58				10.47				10.72				10.29
Net Interest Margin		3.58				3.49				3.50				3.52				3.44
Efficiency (Noninterest Expense/Net Interest Income plus Noninterest Income)		49.48				48.62				50.65				49.50				49.28
Loans to Deposits		90.23				88.15				87.12				90.23				87.12
Investment Securities to Total Assets		15.13				16.14				16.89				15.13				16.89
Tier 1 Leverage (3)		12.36				12.17				12.56				12.36				12.56
Tier 1 Risk-Based Capital (3)		14.46				14.47				15.05				14.46				15.05
Common Equity Tier 1 (CET1) (3)		14.46				14.47				15.05				14.46				15.05
Total Capital (3)		15.56				15.61				16.21				15.56				16.21
Tangible Capital (2)		10.11				10.63				10.79				10.11				10.79
Adjusted Tangible Capital (2)		12.32				12.14				12.57				12.32				12.57
ASSET QUALITY
Loans Past Due 30 – 89 Days	$	2,148			$	3,026			$	984			$	2,148			$	984
Loans Past Due 90 Days or More		6				6				7				6				7
Nonaccrual Loans		17,927				19,946				18,701				17,927				18,701
Nonperforming Loans		17,933				19,952				18,708				17,933				18,708
Other Real Estate Owned		0				0				284				0				284
Other Nonperforming Assets		24				48				82				24				82
Total Nonperforming Assets		17,957				20,000				19,074				17,957				19,074
Individually Analyzed Loans		65,869				66,945				39,497				65,869				39,497
Non-Individually Analyzed Watch List Loans		136,099				131,070				117,746				136,099				117,746
Total Individually Analyzed and Watch List Loans		201,968				198,015				157,243				201,968				157,243
Gross Charge Offs		3,101				431				573				5,728				30,193
Recoveries		133				407				189				655				601
Net Charge Offs		2,968				24				384				5,073				29,592
Net Charge Offs to Average Loans		0.21	%			0.00	%			0.03	%			0.12	%			0.76	%
Credit Loss Reserve to Loans		1.21				1.27				1.30				1.21				1.30
Credit Loss Reserve to Nonperforming Loans		383.81				353.84				364.38				383.81				364.38
Nonperforming Loans to Loans		0.32				0.36				0.36				0.32				0.36
Nonperforming Assets to Assets		0.25				0.28				0.28				0.25				0.28
Total Individually Analyzed and Watch List Loans to Total Loans		3.56				3.55				3.00				3.56				3.00
OTHER DATA
Full Time Equivalent Employees		697				695				666				697				666
Offices		55				55				55				55				55

(1) Core deposits equals deposits less brokered deposits.

(2) Non-GAAP financial measure – see “Reconciliation of Non-GAAP Financial Measures”.

(3) Capital ratios for September 30, 2026 are preliminary until the FR Y-9C is filed.

CONSOLIDATED BALANCE SHEETS (dollars in thousands, except share data)
​	September 30, 2026				December 31, 2025
​	(unaudited)				​
ASSETS
Cash and due from banks	$	53,830			$	57,139
Short-term investments		61,938				84,179
Total cash and cash equivalents		115,768				141,318
​
Securities available-for-sale, at fair value		956,013				1,052,062
Securities held-to-maturity, at amortized cost (fair value of $103,352 and $117,510, respectively)		134,434				133,208
Real estate mortgage loans held-for-sale		2,268				2,707
Loans, net of allowance for credit losses of $68,830 and $68,995		5,611,174				5,306,354
Land, premises and equipment, net		72,390				65,542
Bank owned life insurance		133,549				129,978
Federal Reserve and Federal Home Loan Bank stock		21,420				21,420
Accrued interest receivable		30,253				28,997
Goodwill		4,970				4,970
Other assets		125,688				103,466
Total assets	$	7,207,927			$	6,990,022
​
​
LIABILITIES
Noninterest bearing deposits	$	1,316,701			$	1,221,327
Interest bearing deposits		4,978,095				4,752,023
Total deposits		6,294,796				5,973,350
​
Borrowings – Federal Home Loan Bank advances:
Short-term advance		100,000				170,000
Long-term advance		1,300				1,200
Other borrowings		0				13,000
Total borrowings		101,300				184,200
​
Accrued interest payable		9,701				8,868
Other liabilities		70,036				61,112
Total liabilities		6,475,833				6,227,530
​
STOCKHOLDERS’ EQUITY
Common stock: 90,000,000 shares authorized, no par value
26,070,726 shares issued and 24,819,965 outstanding as of September 30, 2026
26,023,644 shares issued and 25,219,634 outstanding as of December 31, 2025		142,939				136,965
Retained earnings		832,843				788,345
Accumulated other comprehensive income (loss)		(181,766	)			(127,137	)
Treasury stock at cost (1,250,761 shares as of September 30, 2026, 804,010 shares as of December 31, 2025)		(62,011	)			(35,770	)
Total stockholders’ equity		732,005				762,403
Noncontrolling interest		89				89
Total equity		732,094				762,492
Total liabilities and equity	$	7,207,927			$	6,990,022

CONSOLIDATED STATEMENTS OF INCOME (unaudited – in thousands, except share and per share data)
​	Three Months Ended September 30,								Nine Months Ended September 30,
​	2026				2025				2026				2025
NET INTEREST INCOME
Interest and fees on loans
Taxable	$	88,383			$	85,490			$	257,488			$	251,648
Tax exempt		347				287				919				870
Interest and dividends on securities
Taxable		3,889				3,489				11,494				10,335
Tax exempt		3,876				3,915				11,666				11,742
Other interest income		859				1,706				2,922				5,132
Total interest income		97,354				94,887				284,489				279,727
​	​				​				​				​
Interest on deposits		36,467				38,446				106,277				114,015
Interest on short-term borrowings		166				368				2,417				1,888
Total interest expense		36,633				38,814				108,694				115,903
​	​				​				​				​
NET INTEREST INCOME		60,721				56,073				175,795				163,824
​	​				​				​				​
Provision for credit losses		1,200				2,000				4,908				11,800
​	​				​				​				​
NET INTEREST INCOME AFTER PROVISION FOR CREDIT LOSSES		59,521				54,073				170,887				152,024
​	​				​				​				​
NONINTEREST INCOME
Wealth advisory fees		3,153				2,855				9,233				8,389
Investment brokerage fees		535				557				1,570				1,559
Service charges on deposit accounts		3,005				2,921				8,757				8,522
Loan and service fees		3,035				3,419				9,302				9,309
Merchant and interchange fee income		876				892				2,489				2,568
Bank owned life insurance income		1,153				1,567				3,746				2,929
Interest rate swap fee income		0				0				701				20
Mortgage banking income (loss)		88				(6	)			297				67
Other income		429				749				1,684				2,005
Total noninterest income		12,274				12,954				37,779				35,368
​	​				​				​				​
NONINTEREST EXPENSE
Salaries and employee benefits		20,782				20,414				61,571				55,412
Net occupancy expense		2,153				1,877				6,224				5,604
Equipment costs		1,432				1,475				4,305				4,294
Data processing fees and supplies		4,350				4,116				12,983				12,533
Corporate and business development		1,630				1,563				4,365				4,129
FDIC insurance and other regulatory fees		910				878				2,664				2,517
Professional fees		2,123				1,726				5,845				5,812
Other expense		2,741				2,916				7,772				7,859
Total noninterest expense		36,121				34,965				105,729				98,160
​	​				​				​				​
INCOME BEFORE INCOME TAX EXPENSE		35,674				32,062				102,937				89,232
Income tax expense		6,817				5,658				19,162				15,777
NET INCOME	$	28,857			$	26,404			$	83,775			$	73,455
​	​				​				​				​
BASIC WEIGHTED AVERAGE COMMON SHARES		25,027,394				25,703,699				25,142,662				25,708,543
​	​				​				​				​
BASIC EARNINGS PER COMMON SHARE	$	1.15			$	1.03			$	3.33			$	2.86
​
DILUTED WEIGHTED AVERAGE COMMON SHARES		25,237,882				25,821,360				25,320,493				25,804,322
​
DILUTED EARNINGS PER COMMON SHARE	$	1.14			$	1.03			$	3.31			$	2.85

LAKELAND FINANCIAL CORPORATION LOAN DETAIL (unaudited, in thousands)
		September 30, 2026							June 30, 2026							September 30, 2025
Commercial and industrial loans:		​				​										​				​
Working capital lines of credit loans		$	812,472			14.3	%		$	815,493			14.6	%		$	709,645			13.5	%
Non-working capital loans			892,989			15.7				828,878			14.9				808,371			15.4
Total commercial and industrial loans			1,705,461			30.0				1,644,371			29.5				1,518,016			28.9
​		​							​							​
Commercial real estate and multi-family residential loans:
Construction and land development loans			409,682			7.2				439,987			7.9				574,896			10.9
Owner occupied loans			772,098			13.6				804,995			14.4				804,253			15.3
Nonowner occupied loans			992,570			17.5				937,493			16.8				863,085			16.5
Multifamily loans			598,456			10.5				578,151			10.4				413,016			7.9
Total commercial real estate and multi-family residential loans			2,772,806			48.8				2,760,626			49.5				2,655,250			50.6
​		​							​							​
Agri-business and agricultural loans:
Loans secured by farmland			189,685			3.3				180,871			3.2				153,904			2.9
Loans for agricultural production			158,501			2.8				158,522			2.8				186,068			3.6
Total agri-business and agricultural loans			348,186			6.1				339,393			6.0				339,972			6.5
​		​							​							​
Other commercial loans			120,661			2.1				121,060			2.2				91,833			1.7
Total commercial loans			4,947,114			87.0				4,865,450			87.2				4,605,071			87.7
​		​							​							​
Consumer 1-4 family mortgage loans:
Closed end first mortgage loans			308,959			5.5				302,799			5.4				273,580			5.2
Open end and junior lien loans			296,641			5.2				283,099			5.1				241,256			4.6
Residential construction and land development loans			11,166			0.2				12,904			0.2				18,706			0.4
Total consumer 1-4 family mortgage loans			616,766			10.9				598,802			10.7				533,542			10.2
​		​							​							​
Other consumer loans			119,172			2.1				117,953			2.1				112,430			2.1
Total consumer loans			735,938			13.0				716,755			12.8				645,972			12.3
Subtotal			5,683,052			100.0	%			5,582,205			100.0	%			5,251,043			100.0	%
Less: Allowance for credit losses			(68,830	)		​				(70,598	)		​				(68,168	)		​
Net deferred loan fees			(3,048	)		​				(2,580	)		​				(2,424	)		​
Loans, net		$	5,611,174						$	5,509,027			​			$	5,180,451			​

LAKELAND FINANCIAL CORPORATION DEPOSITS AND BORROWINGS (unaudited, in thousands)
	September 30, 2026				June 30, 2026				September 30, 2025
Noninterest bearing demand deposits	$	1,316,701			$	1,292,033			$	1,268,241
Savings and transaction accounts:
Savings deposits		279,489				281,901				281,291
Interest bearing demand deposits		3,751,171				3,828,259				3,689,037
Time deposits:
Deposits of $100,000 or more		749,478				727,412				580,499
Other time deposits		197,957				199,963				205,250
Total deposits	$	6,294,796			$	6,329,568			$	6,024,318
FHLB advances and other borrowings		101,300				71,200				56,200
Total funding sources	$	6,396,096			$	6,400,768			$	6,080,518

LAKELAND FINANCIAL CORPORATION AVERAGE BALANCE SHEET AND NET INTEREST ANALYSIS (UNAUDITED)
		Three Months Ended September 30, 2026										Three Months Ended June 30, 2026										Three Months Ended September 30, 2025
(fully tax equivalent basis, dollars in thousands)		Average Balance				Interest Income			Yield (1)/ Rate			Average Balance				Interest Income			Yield (1)/ Rate			Average Balance				Interest Income			Yield (1)/ Rate
Earning Assets
Loans:
Taxable (2)(3)		$	5,560,289			$	88,383		6.31	%		$	5,507,100			$	85,994		6.26	%		$	5,180,847			$	85,490		6.55	%
Tax exempt (1)			27,455				431		6.23				24,244				363		6.01				24,986				354		5.62
Investments: (1)
Securities			1,151,647				8,796		3.03				1,161,807				8,680		3.00				1,127,094				8,444		2.97
Short-term investments			3,414				27		3.14				3,567				28		3.15				2,795				27		3.83
Interest bearing deposits			94,965				832		3.48				135,984				1,186		3.50				156,918				1,679		4.25
Total earning assets		$	6,837,770			$	98,469		5.71	%		$	6,832,702			$	96,251		5.65	%		$	6,492,640			$	95,994		5.87	%
Less:  Allowance for credit losses			(70,473	)									(69,959	)									(67,115	)
Nonearning Assets
Cash and due from banks			59,654										64,197										62,671
Premises and equipment			72,013										69,499										64,391
Other nonearning assets			297,457										294,224										298,084
Total assets		$	7,196,421									$	7,190,663									$	6,850,671
Interest Bearing Liabilities
Savings deposits		$	280,866			$	39		0.06	%		$	287,520			$	41		0.06	%		$	284,553			$	41		0.06	%
Interest bearing checking accounts			3,820,281				28,076		2.92				3,867,392				28,184		2.92				3,731,706				31,382		3.34
Time deposits:
In denominations under $100,000			199,739				1,555		3.09				201,696				1,576		3.13				204,997				1,678		3.25
In denominations over $100,000			743,563				6,797		3.63				728,345				6,578		3.62				563,920				5,345		3.76
Short-term borrowings			16,957				166		3.88				47,286				468		3.97				31,739				368		4.60
Long-term borrowings			1,249				0		0.00				1,200				0		0.00				1,200				0		0.00
Total interest bearing liabilities		$	5,062,655			$	36,633		2.87	%		$	5,133,439			$	36,847		2.88	%		$	4,818,115			$	38,814		3.20	%
Noninterest Bearing Liabilities
Demand deposits			1,293,641										1,227,721										1,244,381
Other liabilities			70,992										68,970										70,747
Stockholders’ Equity			769,133										760,533										717,428
Total liabilities and stockholders’ equity		$	7,196,421									$	7,190,663									$	6,850,671
Interest Margin Recap
Interest income/average earning assets							98,469		5.71	%							96,251		5.65	%							95,994		5.87	%
Interest expense/average earning assets							36,633		2.13								36,847		2.16								38,814		2.37
Net interest income and margin						$	61,836		3.58	%						$	59,404		3.49	%						$	57,180		3.50	%

(1)		Tax exempt income was converted to a fully taxable equivalent basis at a 21 percent tax rate. The tax equivalent rate for tax exempt loans and tax-exempt securities acquired after January 1, 1983, included the Tax Equity and Fiscal Responsibility Act of 1982 (“TEFRA”) adjustment applicable to nondeductible interest expenses. Taxable equivalent basis adjustments were $1.12 million, $1.10 million, and $1.11 million in the three-month periods ended September 30, 2026, June 30, 2026, and September 30, 2025, respectively.
(2)		Loan fees, which are immaterial in relation to total taxable loan interest income for the three-month periods ended September 30, 2026, June 30, 2026, and September 30, 2025, are included as taxable loan interest income.
(3)		Nonaccrual loans are included in the average balance of taxable loans.

Reconciliation of Non-GAAP Financial Measures

Tangible common equity, adjusted tangible common equity, tangible assets, adjusted tangible assets, tangible book value per common share, tangible common equity to tangible assets, adjusted tangible common equity to adjusted tangible assets, and pretax pre-provision earnings are non-GAAP financial measures calculated based on GAAP amounts. Tangible common equity is calculated by excluding the balance of goodwill and other intangible assets from the calculation of equity, net of deferred tax. Tangible assets are calculated by excluding the balance of goodwill and other intangible assets from the calculation of total assets, net of deferred tax. Adjusted tangible assets and adjusted tangible common equity remove the fair market value adjustment impact of the available-for-sale investment securities portfolio in accumulated other comprehensive income (loss) (“AOCI”). Tangible book value per common share is calculated by dividing tangible common equity by the number of shares outstanding less true treasury stock. Pretax pre-provision earnings is calculated by adding net interest income to noninterest income and subtracting noninterest expense. Because not all companies use the same calculation of tangible common equity and tangible assets, this presentation may not be comparable to other similarly titled measures calculated by other companies. However, management considers these measures of the company’s value meaningful to understanding of the company’s financial information and performance.

A reconciliation of these non-GAAP financial measures is provided below (dollars in thousands, except per share data).

	Three Months Ended												Nine Months Ended
	September 30, 2026				June 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
Total Equity	$	732,094			$	773,374			$	747,503			$	732,094			$	747,503
Less: Goodwill		(4,970	)			(4,970	)			(4,970	)			(4,970	)			(4,970	)
Plus: DTA Related to Goodwill		1,167				1,167				1,167				1,167				1,167
Tangible Common Equity		728,291				769,571				743,700				728,291				743,700
Market Value Adjustment in AOCI		181,273				123,959				140,165				181,273				140,165
Adjusted Tangible Common Equity		909,564				893,530				883,865				909,564				883,865
Assets	$	7,207,927			$	7,242,959			$	6,895,028			$	7,207,927			$	6,895,028
Less: Goodwill		(4,970	)			(4,970	)			(4,970	)			(4,970	)			(4,970	)
Plus: DTA Related to Goodwill		1,167				1,167				1,167				1,167				1,167
Tangible Assets		7,204,124				7,239,156				6,891,225				7,204,124				6,891,225
Market Value Adjustment in AOCI		181,273				123,959				140,165				181,273				140,165
Adjusted Tangible Assets		7,385,397				7,363,115				7,031,390				7,385,397				7,031,390
Ending Common Shares Issued		24,994,459				25,028,859				25,704,243				24,994,459				25,704,243
Tangible Book Value Per Common Share	$	29.14			$	30.75			$	28.93			$	29.14			$	28.93
Tangible Common Equity/Tangible Assets		10.11	%			10.63	%			10.79	%			10.11	%			10.79	%
Adjusted Tangible Common Equity/Adjusted Tangible Assets		12.32	%			12.14	%			12.57	%			12.32	%			12.57	%
Net Interest Income	$	60,721			$	58,301			$	56,073			$	175,795			$	163,824
Plus:  Noninterest Income		12,274				12,572				12,954				37,779				35,368
Minus:  Noninterest Expense		(36,121	)			(34,457	)			(34,965	)			(105,729	)			(98,160	)
Pretax Pre-Provision Earnings	$	36,874			$	36,416			$	34,062			$	107,845			$	101,032

Contact
Lisa M. O’Neill
Executive Vice President and Chief Financial Officer
(574) 267-9125
lisa.oneill@lakecitybank.com

MEMPHIS, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO) today announced that Jamere Jackson has resigned as Chief Financial Officer effective November 25, 2026, after which he will assume the position of Chief Financial Officer of FedEx Corporation.  “During Jamere’s six-year tenure at AutoZone, he was a key contributor in helping shape the strategies we implemented to drive record sales, earnings, and earnings per share.  I appreciate his many contributions to our success and wish him well in his future endeavors,” said Phil Daniele, President and Chief Executive Officer.  “We have commenced  an external search for his successor.  I am confident the experienced, deeply tenured, finance and accounting team we have will ensure seamless continuity and will deliver exceptional financial leadership.  Our strategies are well established, and we believe we are on track for a solid fiscal 2027.”

About AutoZone (NYSE: AZO)

As of August 29, 2026, the Company had 6,863 stores in the U.S., 1,001 in Mexico and 167 in Brazil for a total store count of 8,031.

AutoZone is a leading retailer and distributor of automotive replacement parts and accessories in the Americas. Each store carries an extensive product line for cars, sport utility vehicles, vans and light duty trucks, including new and remanufactured automotive hard parts, maintenance items, accessories, and non-automotive products. The majority of stores have a commercial sales program that provides prompt delivery of parts and other products and commercial credit to local, regional and national repair garages, dealers, service stations, fleet owners and other accounts. AutoZone also sells automotive hard parts, maintenance items, accessories and non-automotive products through www.autozone.com, and our commercial customers can make purchases through www.autozonepro.com. Additionally, we sell the ALLDATA brand of automotive diagnostic, repair, collision and shop management software through www.alldata.com. We also provide product information on our Duralast branded products through www.duralastparts.com. AutoZone does not derive revenue from automotive repair or installation services.

Certain statements herein constitute forward-looking statements that are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically use words such as “believe,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy,” “seek,” “may,” “could” and similar expressions. These statements are based on assumptions and assessments made by our management in light of experience, historical trends, current conditions, expected future developments and other factors that we believe appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including without limitation: product demand, due to changes in fuel prices, miles driven or otherwise; energy prices; weather, including extreme temperatures and natural disasters; competition; credit market conditions; cash flows; access to financing on favorable terms; future stock repurchases; the impact of recessionary conditions; consumer debt levels; changes in laws or regulations; risks associated with self-insurance; war and the prospect of war, including terrorist activity; public health issues; inflation, including wage inflation; exchange rates; the ability to hire, train and retain qualified employees, including members of management; construction delays; failure or interruption of our information technology systems; issues relating to the confidentiality, integrity or availability of information, including due to cyber-attacks; historic sales and profit growth rate sustainability; downgrade of our credit ratings; damage to our reputation; challenges associated with doing business in and expanding into international markets; origin and raw material costs of suppliers; inventory availability; disruption in our supply chain; tariffs, trade policies and other geopolitical factors; new accounting standards; our ability to execute our growth initiatives; and other business interruptions. These and other risks and uncertainties are discussed in more detail in the “Risk Factors” section contained in Item 1A under Part 1 of our Annual Report on Form 10-K for the year ended August 30, 2025. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those contemplated by such forward-looking statements. Events described above and in the “Risk Factors” section could materially and adversely affect our business. However, it is not possible to identify or predict all such risks and other factors that could affect these forward-looking statements. Forward-looking statements speak only as of the date made. Except as required by applicable law, we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Financial: Brian Campbell at (901) 495-7005, brian.campbell@autozone.com

Media:  Jennifer Hughes at (901) 495-6022, jennifer.hughes@autozone.com

TORONTO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced that it will be presenting at the Planet MicroCap Toronto 2026 Powered by MicroCapClub on Wednesday, October 28, 2026 at 2:00 PM Eastern Time at the Arcadian Loft in Toronto. Peter Evans, Chief Executive Officer of Xtract One Technologies, will host the presentation and answer questions at the conclusion.

To access the live presentation, please use the following information:

Planet MicroCap Toronto 2026 Powered by MicroCapClub
Date: Wednesday, October 28, 2026
Time: 2:00 PM Eastern Time
Webcast: https://event.summitcast.com/view/iiVo9HYfz9sL9CC5m4Dgpv/WmUY3Rxiief5qYH6Qf6s2U

If you would like to book one-on-one investor meetings with Xtract One and attend the Planet MicroCap Toronto 2026, please make sure you are registered here: REGISTER

One-on-one meetings will be scheduled and conducted in person at the conference venue: Arcadian Loft, 401 Bay St., Simpson Tower, 8th Floor, Toronto, ON, M5H 2Y4.

The Planet MicroCap Toronto 2026 website is available here: HOME PAGE

If you can’t make the live presentation, all company presentations will be available directly on the conference event platform under the Agenda tab: AGENDA

To learn more about Xtract One, visit www.xtractone.com.

About Planet MicroCap
Planet MicroCap hosts the highest quality microcap in-person events in North America. The mission is to bring the best microcap investors, companies, and allocators together to gather, connect, and grow. For more information about Planet MicroCap, please visit https://planetmicrocap.com/.

About MicroCapClub
MicroCapClub is an exclusive forum for experienced microcap investors to share and discuss microcap companies trading on global markets. Since 2011, members have profiled 1,500 or more microcap companies, with 300 or more turning into multi-baggers. For more information, visit https://microcapclub.com/.

About Xtract One
Xtract One Technologies is a leading technology-driven provider of threat detection and security solutions leveraging AI to deliver seamless and secure experiences. The Company makes unobtrusive weapons and threat detection systems that are designed to assist facility operators in prioritizing- and delivering improved “Walk-right-In” experiences while enhancing safety. Xtract One’s innovative portfolio of AI-powered Gateway solutions excels at allowing facilities to discreetly screen and identify weapons and other threats at points of entry and exit without disrupting the flow of traffic. With solutions built to serve the unique market needs for schools, hospitals, arenas, stadiums, manufacturing, distribution, and other customers, Xtract One is recognized as a market leader delivering the highest security in combination with the best individual experience. For more information, visit www.xtractone.com or connect on Facebook, X, and LinkedIn.

About Threat Detection Systems
Xtract One solutions, when properly configured, deployed, and utilized, are designed to help enhance safety and reduce threats. Given the wide range of potential threats in today’s world, no threat detection system is 100% effective. Xtract One solutions should be utilized as one element in a multilayered approach to physical security.

Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance and customer contracts, are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, but are not limited to, the risks detailed from time to time in the continuous disclosure filings made by the Company with securities regulations. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

For further information, please contact:
Xtract One Inquiries: info@xtractone.com, http://www.xtractone.com
Investor Relations: Mark Kuindersma, LodeRock Advisors, mark.kuindersma@loderockadvisors.com, 519-501-0545
Media Contact: Kristen Aikey, JMG Public Relations, kristen@jmgpr.com, 212-206-1645

BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that it will host a conference call and webcast to report third quarter 2026 financial results and operational highlights on Monday, November 9, 2026, at 8:30 a.m. ET.

To listen to the conference call, register at this link. To view the webcast, register at this link.

A replay will be available under “IR Events” in the Investors section of the Company’s website at https://ir.tonixpharma.com/news-events/ir-events.

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs. TONMYA^® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace^® SymTouch^® (sumatriptan injection 3 mg) and Tosymra^® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate the potential of TNX-102 SL in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including Phase 2-ready monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S., and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, TNX-1500 (anti-CD40L mAb) is a Phase 2-ready, third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com.

*Tonix’s product development candidates, including TNX-102 SL for new, unapproved indications, are investigational new drugs or biologics. Their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA^® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Deborah Elson
Tonix Pharmaceuticals
deborah.elson@tonixpharma.com
investor.relations@tonixpharma.com  

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com

Media Contacts
Andrea Cohen
Sam Brown Inc.
(917) 209-7163
andreacohen@sambrown.com

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Centauri Minerals Inc. (TSX-V: CENT; OTCQX: CNTIF), a mineral exploration company, has qualified to trade on the OTCQX® Best Market. Centauri Minerals Inc. upgraded to OTCQX from the Pink Limited™ Market.

Centauri Minerals Inc. begins trading today on OTCQX under the symbol “CNTIF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.

Sam Leung, Chief Executive Officer and Director of Centauri, commented as follows: “As a new public company on the TSX Venture Exchange, we are pleased to begin trading on the OTCQX, which will increase our visibility and accessibility to our current and new U.S. and global shareholders. Many shareholders of Aldebaran Resources and Regulus Resources have benefited from this optionality, which is now available to Centauri shareholders as we begin drilling at the Rio Grande gold-copper project.”

Trading in non-U.S. North American securities on OTC Markets reached $29.38B in the third quarter of 2026, representing an 84.22% increase over Q3 2025. OTC Markets recorded $203.47B in total dollar volume in Q3. North America ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Centauri Minerals Inc.
Centauri Minerals Inc. is a mineral exploration company focused on Northern Argentina, a mining region of increasing global significance. Centauri holds a 100%-interest in a portfolio of exploration projects spanning approximately 40,000 hectares in the provinces of Salta, Jujuy, and Catamarca, which was spun-out from Aldebaran Resources Inc. The most advanced is the Rio Grande gold-copper project located in Salta, which has an independent National Instrument 43-101 compliant mineral resource estimate that highlights significant gold, copper and silver quantities. Centauri has offices and facilities in Salta, Argentina and Vancouver, Canada.

For further information, please visit the Centauri website and subscribe to the Centauri news list.
Website: www.centauriminerals.com

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

TORONTO, Oct. 26, 2026 (GLOBE NEWSWIRE) — J. P. Morgan Asset Management (JPMAM)* today announced the final October 2026 cash distributions for the below listed JPMorgan ETFs. The JPMorgan ETFs trade on the Toronto Stock Exchange (TSX). Unitholders of record on November 2, 2026 will receive cash distributions payable on November 6, 2026. Details of the “per unit” distributions are as follows:

JPMorgan ETF name	Ticker symbol	Distribution per unit ($)	Payment frequency
JPMorgan US Equity Premium Income Active ETF	JEPI	0.14052	Monthly
JPMorgan Nasdaq Equity Premium Income Active ETF	JEPQ	0.27889	Monthly
JPMorgan US Equity Premium Income Active ETF – CAD Hedged	JEPH	0.15435	Monthly
JPMorgan Nasdaq Equity Premium Income Active ETF – CAD Hedged	JPQH	0.26929	Monthly

To learn more about the JPMorgan ETFs, please visit www.jpmorgan.com/ca/adivsors

For more information, please e-mail: jpmam.canada@jpmorgan.com

About J.P. Morgan Asset Management

J.P. Morgan Asset Management, with assets under management of US$4.4 Trillion¹ (as of December 31, 2025), is a global leader in investment management. J.P. Morgan Asset Management’s clients include institutions, retail investors and high net worth individuals in every major market throughout the world. J.P. Morgan Asset Management offers global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity. For more information: www.jpmorganassetmanagement.com.

* Legal entity in Canada: JPMorgan Asset Management (Canada) Inc.

¹ Source: J.P. Morgan Asset Management, as of December 30, 2025.

Commissions, trailing commissions, management fees and expenses all may be associated with ETF investments. Please read the prospectus before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated.

Past returns are not necessarily indicative of future performance. You should not rely on or view any past performance as a guarantee of future investment performance.

Nasdaq®, Nasdaq-100 Index®, Nasdaq 100® and NDX® are registered trademarks of Nasdaq, Inc. (which with its affiliates is referred to as the “Corporations”) and are licensed for use by J.P. Morgan Asset Management (Canada) Inc. and J.P. Morgan Investment Management Inc. JPMorgan Nasdaq Equity Premium Income Active ETF has not been passed on by the Corporations as to its legality or suitability. This ETF is not issued, endorsed, sold, or promoted by the Corporations. THE CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THIS ETF.

This communication is issued in Canada, by JPMorgan Asset Management (Canada) Inc. is a registered Portfolio Manager and Exempt Market Dealer in all Canadian provinces and territories except the Yukon, and an Investment Fund Manager in British Columbia, Ontario, Quebec, and Newfoundland and Labrador. It is also a Derivatives Adviser in Manitoba, a Commodity Trading Manager in Ontario, and a Derivatives Portfolio Manager in Quebec.​

J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — Xali Gold Corp. (TSXV:XGC) (“Xali Gold” or the “Company”) is pleased to announce that it has submitted its Ficha Técnica Ambiental (“FTA”) application to Peru’s Ministry of Energy and Mines (“MINEM”) for resource confirmation and exploration drilling at the Pico Machay Gold Project (“Pico Machay” or the “Project”) in Huancavelica, Peru. The Company has also signed a contract with Geologia Estudios Medio Ambientales Drilling & Construction S.R.L. (“GEMA”) to carry out its initial 3,000-metre (“m”) diamond drilling program.

The submission follows receipt of MINEM’s documentation regarding attendance at the October 7, 2026, public information workshop, the final item outstanding when the Company announced completion of the application on October 21, 2026. Based on guidance received, the Company anticipates a review and approval period of approximately 10 days following submission, subject to regulatory review and any requests for additional information.

“With the FTA submitted and our drill contractor lined up, we are advancing the permitting and operational preparations needed to begin drilling at Pico Machay,” said Joanne Freeze, President and CEO of Xali Gold. “Our immediate priority is to obtain the geological and assay data needed to support an updated mineral resource estimate. That estimate will underpin a preliminary economic assessment (“PEA”), allowing us to evaluate potential development options and project economics using an updated technical foundation.”

Drilling Contractor

GEMA and its key personnel specialize in exploration and geotechnical diamond drilling across Peru. The team’s experience spans diverse terrain across Peru, from high-altitude mountain sites to jungle and dry coastal areas. Their project experience includes Fresnillo Peru’s Santo Domingo project (4,600 – 4,950 masl), Nexa Resources’ Sinaycocha, Santa Rosa and El Porvenir projects (above 4,000 masl), as well as Buenaventura’s Tantahuatay and La Zanja operations. Team members also worked at Tahoe Resources’ La Arena and Shahuindo mines, where Wilder Garcia, Xali Gold’s Exploration Manager, oversaw their work.

GEMA has two diamond drill rigs ready for the initial 3,000 m program at Pico Machay, with HQ-diameter core and individual holes planned to reach depths of approximately 150 to 300 m. Approximately 2,000 m of the initial 3,000 m program will twin 10% of the historical reverse circulation holes within the historical resource area to help verify previous results and improve understanding of the controls to gold mineralization. The FTA application covers a broader program totalling up to 20,000 m from 20 platforms, providing scope for additional resource definition and exploration drilling beyond this initial program.

The Company is targeting commencement of drilling in early November 2026, subject to receipt of the required permits.

About Pico Machay

Located within the Southern Peru Epithermal Gold-Silver Belt, Pico Machay sits in a historically productive mining district in the Western Cordillera of the Andes (click here for location map). The Project benefits from existing infrastructure and a mining-friendly community eager to partner in sustainable development.

Xali Gold remains confident in the significant upside potential at Pico Machay, which hosts a historical resource and several untested exploration targets on the Project. Various historical engineering studies at Pico Machay were completed through 2009 and evaluated the potential for a low-cost, low strip-ratio, open-pit heap-leach operation. Given that those studies were based on a long-term gold price of $700/oz and several exploration targets remain untested, Xali Gold considers the upside potential to be very strong.

About Xali Gold

Xali Gold is a gold and silver exploration company focused on advancing opportunities in the Americas. The Company is focused on the exploration and development of Pico Machay, an advanced exploration-stage gold project in Peru with a near-term production goal. 

The Company’s approach to community engagement and responsible development is guided by strong governance principles and Board oversight that support long-term stakeholder relationships.

Joanne C. Freeze, P.Geo. is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the contents of this release.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

On behalf of the Board of Xali Gold Corp.

“Joanne Freeze” P.Geo.
President, CEO and Director

For further information please contact:
Joanne Freeze, President & CEO
Tel: + 1 (604) 512-3359
info@xaligold.com

Forward-looking Disclaimer
This press release contains forward-looking information within the meaning of Canadian securities laws (“forward-looking statements”). Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, plans, postulate and similar expressions, or are those, which, by their nature, refer to future events. All statements that are not statements of historical fact are forward-looking statements.

Forward-looking statements in this press release include, without limitation, statements regarding: the anticipated timing of FTA review and approval; the scope, timing and commencement of the planned drilling program; the anticipated deployment of two drill rigs by GEMA; further resource definition and exploration drilling; and the preparation of an updated mineral resource estimate and preliminary economic assessment to evaluate the Project’s development potential.

These forward-looking statements are made as of the date of this press release. Although the Company believes the forward-looking statements in this press release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.

Known risk factors and assumptions include risks associated with exploration and project development; accessing further funding and related dilution: continuing its projected growth, or being fully able to implement its business strategies; the calculation of mineral resources and additional work required to convert historical resources to current mineral resources; the nature, quality and quantity of any mineral deposits that may be located on the project; operational risks associated with mining and mineral processing; fluctuations in metal prices and assumptions including costs; title matters; government regulation; obtaining and renewing necessary consents, authorizations, licenses and permits; environmental liability and insurance; reliance on key personnel; local community opposition; currency fluctuations; labour disputes; competition; variations in market conditions, and the volatility of our common share price and volume; future sales of shares by existing shareholders; and other risk factors described in Xali Gold’s MD&A and other filings with Canadian securities regulators, which may be viewed at www.sedarplus.ca. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Xali Gold expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws.